Siemens eyes digital pathology with BioImagene investment
Siemens Venture Capital has invested in BioImagene, a provider of scalable digital pathology solutions, following a recent closing of a $26 million series D financing round led by Burrill & Company.
Additionally, Ajit Singh, PhD, from the Image and Knowledge Group of Siemens Healthcare was appointed CEO of BioImagene following the financing round.
The Cupertino, Calif.-based BioImagene said it will use the investment to scale operations and accelerate the adoption of digital pathology with continued product development and expansion in the European and Asian markets.
BioImagene provides digital pathology solutions for acquiring, viewing, managing, analyzing, reporting and sharing images in the pathology laboratory. Additional investors in BioImagene include Ascension Health Ventures, Artiman Ventures, Burrill, ICCP Venture Partners and National Healthcare Services, the company said.
Additionally, Ajit Singh, PhD, from the Image and Knowledge Group of Siemens Healthcare was appointed CEO of BioImagene following the financing round.
The Cupertino, Calif.-based BioImagene said it will use the investment to scale operations and accelerate the adoption of digital pathology with continued product development and expansion in the European and Asian markets.
BioImagene provides digital pathology solutions for acquiring, viewing, managing, analyzing, reporting and sharing images in the pathology laboratory. Additional investors in BioImagene include Ascension Health Ventures, Artiman Ventures, Burrill, ICCP Venture Partners and National Healthcare Services, the company said.